|
1）Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002; 346(26): 2053-60
|
|
|
|
2）Debiec H, Lefeu F, Kemper MJ, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med. 2011; 364(22): 2101-10
|
|
|
|
|
|
3）Beck LH, Jr., Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361(1): 11-21
|
|
|
|
|
|
4）Prunotto M, Carnevali ML, Candiano G, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol. 2010; 21(3): 507-19
|
|
|
|
|
|
5）Kim S, Chin HJ, Na KY, et al. Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy. Nephron Clin Pract. 2011; 117(3): c253-8
|
|
|
|
|
|
6）Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med. 2011; 364(7): 616-26
|
|
|
|
|
|
7）Border WA, Ward HJ, Kamil ES, et al. Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen. J Clin Invest. 1982; 69(2): 451-61
|
|
|
|
|
|
8）Yokota Y. ノックアウトマウスを用いたホスホリパーゼA2 受容体の機能解析 [Functional analysis of phospholipase A2 receptor by gene knockout studies]. Yakugaku Zasshi. 2001; 121(1): 23-33
|
|
|
|
|
9）Hofstra JM, Beck LH, Jr., Beck DM, et al. Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011; 6(6): 1286-91
|
|
|
|
|
|
10）Beck LH, Jr., Salant DJ. Membranous nephropathy: recent travels and new roads ahead. Kidney Int. 2010; 77(9): 765-70
|
|
|
|
|
|
11）Qin W, Beck LH, Jr., Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011; 22(6): 1137-43
|
|
|
|
|
|
12）Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011; 26(8): 2526-32
|
|
|
|
|
|
13）Wakui H, Imai H, Komatsuda A, et al. Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN). Clin Exp Immunol. 1999; 118(3): 445-50
|
|
|
|
|
|
14）Bruschi M, Carnevali ML, Murtas C, et al. Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. J Proteomics. 2011; 74(10): 2008-17
|
|
|
|
|
|
15）Murtas C, Bruschi M, Candiano G, et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol. 2012; 7(9): 1394-1400
|
|
|
|
|
|
16）Debiec H, Martin L, Jouanneau C, et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy. Am J Transplant. 2011; 11(10): 2144-52
|
|
|
|
|
|
17）Ronco P, Debiec H. Pathogenesis of membranous nephropathy: recent advances and future challenges. Nat Rev Nephrol. 2012; 8(4): 203-13
|
|
|
|
|